Rachel Turk

Rachel Turk serves as a key procurement lead within the National Cancer Institute, supporting the agency’s mission to accelerate cancer research through advanced scientific and technical solutions. She manages complex acquisitions for high-capability research infrastructure, diagnostic platforms, and translational biotechnology services, ensuring alignment with NIH’s strategic priorities in precision medicine and genomic analysis. Her procurement activities focus on securing specialized R&D capabilities from industry partners capable of delivering innovative, scalable solutions for cancer diagnostics and therapeutic development. She works closely with scientific stakeholders to translate technical requirements into compliant, performance-based contract vehicles that support mission-critical research pipelines. Her primary contractor relationships center on Roche Diagnostics Corporation, reflecting a consistent reliance on large, established biotechnology firms with proven capabilities in molecular diagnostics, assay development, and clinical-grade data analytics. These partnerships are typically structured as cost-reimbursement or fixed-price incentive contracts for advanced research services, often involving multi-year performance periods to support long-term scientific objectives. While Roche is the dominant partner, her portfolio also engages other high-capacity technical service providers with deep expertise in biotech R&D and scientific consulting. Rachel’s contracting patterns show no use of socioeconomic set-asides, with 100% of awards issued under full and open competition. This reflects a procurement strategy prioritizing technical excellence and scalability over socioeconomic preferences, aligning with the NCI’s urgent need for mission-critical capabilities that require specialized infrastructure and regulatory compliance. Her procurement focus is heavily concentrated in NAICS 541714 (Research and Development in Biotechnology), with significant activity in 541690 (Scientific and Technical Consulting Services) and 541990 (Other Professional, Scientific, and Technical Services). She routinely procures next-generation sequencing support, biomarker validation services, bioinformatics platforms, and clinical trial analytics systems, demonstrating deep expertise in the technical domains of molecular oncology and translational research infrastructure.